Search alternatives:
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
mg decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 we » _ we (Expand Search), 5 wt (Expand Search), 5 w (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
mg decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 we » _ we (Expand Search), 5 wt (Expand Search), 5 w (Expand Search)
-
581
-
582
-
583
-
584
-
585
-
586
Sequence of <i>DpAP2</i> promoter.
Published 2024“…Transgenic <i>D</i>. <i>parva</i> showed a higher carotenoid content (3.18 mg/g DW) compared with control group (2.13 mg/g DW) at 9 d. …”
-
587
Predicted <i>cis</i>-acting elements in <i>DpAP2</i> promoter.
Published 2024“…Transgenic <i>D</i>. <i>parva</i> showed a higher carotenoid content (3.18 mg/g DW) compared with control group (2.13 mg/g DW) at 9 d. …”
-
588
-
589
-
590
Demonstrates that AS-IV mitigates the injury to the lungs and colon caused by LPS.
Published 2024“…<p>(A) The therapeutic impact of AS-IV in decreasing the severity of lung pathology (Bar = 10μm and 50 μm). …”
-
591
-
592
-
593
-
594
Image_1_IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt.TIF
Published 2021“…</p><p>Objectives: To investigate the cellular and molecular pathways affected by IL-12p40/IL-23p40 blockade with ustekinumab in the synovium of PsA patients.</p><p>Methods: Eleven PsA patients with at least one inflamed knee or ankle joint were included in a 24-week single-center open-label study and received ustekinumab 45 mg/sc according to standard care at week 0, 4, and 16. …”
-
595
-
596
Simulated effects of increased pCREB combined with decreased pCaMKIIα on bistability.
Published 2022“…However, decreasing <i>k</i><sub><i>basalp_CaMKII</i></sub> by ~50% blocked the bistable switch (red). …”
-
597
-
598
-
599
-
600